Literature DB >> 33248473

The place for remdesivir in COVID-19 treatment.

Barnaby Young1, Thuan Tong Tan2, Yee Sin Leo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33248473     DOI： 10.1016/S1473-3099(20)30911-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  31 in total

Review 1.  COVID-19: Main findings after a year and half of unease and the proper scientific progress (Review).

Authors:  Marius Traian Leretter; Dan Dumitru Vulcanescu; Florin George Horhat; Anamaria Matichescu; Mircea Rivis; Laura-Cristina Rusu; Alexandra Roi; Robert Racea; Ioana Badea; Cristina Adriana Dehelean; Alexandra Mocanu; Delia Ioana Horhat
Journal:  Exp Ther Med       Date:  2022-05-04       Impact factor: 2.751

Review 2.  A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.

Authors:  Parastoo Tarighi; Samane Eftekhari; Milad Chizari; Mahsa Sabernavaei; Davod Jafari; Parastoo Mirzabeigi
Journal:  Eur J Pharmacol       Date:  2021-01-20       Impact factor: 5.195

Review 3.  COVID-19 pandemic: the implications of the natural history, challenges of diagnosis and management for care in sub-Saharan Africa.

Authors:  Lawrence Omo-Aghoja; Emuesiri Goodies Moke; Kenneth Kelechi Anachuna; Adrian Itivere Omogbiya; Emuesiri Kohworho Umukoro; Pere-Ebi Yabrade Toloyai; Tarela Melish Elias Daubry; Anthony Taghogho Eduviere
Journal:  Beni Suef Univ J Basic Appl Sci       Date:  2021-03-17

4.  Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.

Authors:  Roxanna Hajbabaie; Matthew T Harper; Taufiq Rahman
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.927

5.  Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.

Authors:  Keivan Ranjbar; Mohsen Moghadami; Alireza Mirahmadizadeh; Mohammad Javad Fallahi; Vahid Khaloo; Reza Shahriarirad; Amirhossein Erfani; Zohre Khodamoradi; Mohammad Hasan Gholampoor Saadi
Journal:  BMC Infect Dis       Date:  2021-04-10       Impact factor: 3.090

6.  Real-life use of remdesivir in hospitalized patients with COVID-19.

Authors:  C Garcia-Vidal; F Meira; A Cózar-Llistó; G Dueñas; P Puerta-Alcalde; N Garcia-Pouton; M Chumbita; C Cardozo; M Hernandez-Meneses; R Alonso-Navarro; V Rico; D Agüero; M Bodro; L Morata; C Jordan; C Lopera; J Ambrosioni; F Segui; N Grafia; P Castro; F García; J Mensa; J A Martínez; G Sanjuan; A Soriano
Journal:  Rev Esp Quimioter       Date:  2021-03-06       Impact factor: 1.553

7.  Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study.

Authors:  Gil Darquennes; Pascal Le Corre; Olivier Le Moine; Gwenolé Loas
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07

8.  A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.

Authors:  Fernando Santos-Beneit; Vytautas Raškevičius; Vytenis A Skeberdis; Sergio Bordel
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

9.  Targeted Mitochondrial Therapy With Over-Expressed MAVS Protein From Mesenchymal Stem Cells: A New Therapeutic Approach for COVID-19.

Authors:  Amirhesam Babajani; Pooya Hosseini-Monfared; Samin Abbaspour; Elham Jamshidi; Hassan Niknejad
Journal:  Front Cell Dev Biol       Date:  2021-06-11

10.  Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned.

Authors:  Lars Dölken; August Stich; Christoph D Spinner
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.